A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT07481981 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: Treprostinil Palmitil Inhalation Powder
DRUG: Placebo

Sponsor

Insmed Incorporated